



Patent Applicant
Attorney Docket No. PC9838

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 1st day of July, 2003.

By

Deanna Miller
(Signature of person mailing)
Deanna Miller

(Typed or printed name of person)

7/17/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
IN RE APPLICATION OF: William J. Curatolo, et al. :

APPLICATION NO.: 10/310,232 : Examiner: Unknown

FILING DATE: December 5, 2002 : Group Art Unit: 1615

TITLE: ENCAPSULATED SOLUTION DOSAGE FORMS :
OF SERTRALINE

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

July 1, 2003


Carmella A. O'Gorman

Carmella A. O'Gorman
Attorney for Applicant(s)
Reg. No. 33,749

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686--1847

BEST AVAILABLE COPY

RECEIVED
JUL 07 2003
TECH CENTER 1600/2900



INFORMATION DISCLOSURE CITATION									ATTY. DOCKET NO. PC9838B		SERIAL NO. 10/310,232		
(Use several sheets if necessary)									APPLICANT William J. Curatolo, et al.				
									FILING DATE December 5, 2002		GROUP 1615		
U.S. PATENT DOCUMENTS													
EXAMINER INITIALS	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	4	5	3	6	5	1	8	08/20/85	Welch, Jr. et al.	514	647	
	US	4	6	2	4	4	4	3	11/25/86	Eidsmore	251	65	
	US	4	6	9	4	8	6	0	09/22/87	Eidsmore	137	614.21	
	US	4	7	0	5	0	7	0	11/10/87	Eidsmore	137	614.21	
	US	4	7	9	2	1	1	3	12/20/88	Eidsmore	251	65	
	US	4	7	9	3	3	7	9	12/27/88	Eidsmore	137	614.19	
	US	4	7	9	2	4	4	8	12/20/88	Ranade	424	438	
	US	4	7	9	7	2	8	6	01/10/89	Thakkar et al.	424	456	
	US	4	8	0	3	0	7	6	02/07/89	Ranade	424	438	
	US	4	8	4	7	0	9	2	07/11/89	Thakkar et al.	424	456	
	US	4	8	7	6	2	8	2	10/24/89	Robertson et al.	514	554	
	US	4	8	8	7	6	1	7	12/19/89	Ruppert et al.	131	70	
	US	4	9	4	0	7	3	1	07/10/90	Bick	514	657	
	US	4	9	6	2	1	2	8	10/09/90	Doogan et al.	514	647	
	US	4	9	7	1	9	9	8	11/20/90	Wurtman et al.	514	654	
	US	5	0	2	6	7	0	7	06/25/91	Nixon et al.	514	255	
	US	5	0	3	3	5	0	5	07/23/91	Eidsmore	137	505.39	
	US	5	0	4	3	1	0	9	08/27/91	Coates et al.	264	13	
	US	5	0	6	1	7	2	8	10/29/91	Koe	514	520	
	US	5	1	0	4	8	9	9	04/14/92	Young et al.	514	646	
	US	5	1	1	2	6	1	9	05/12/92	Thakkar et al.	424	456	
	US	5	1	3	0	3	3	8	07/14/92	Bacopoulos	514	646	
	US	5	1	3	5	9	4	7	08/04/92	Robertson et al.	514	466	
	US	5	2	0	2	3	7	6	04/13/93	Coates et al.	524	583	
	US	5	2	3	8	0	1	6	08/24/93	Eidsmore	137	1	
	US	5	3	7	1	0	9	2	12/06/94	Johnson	514	321	
	US	5	7	4	1	8	0	7	04/21/98	Thomas	514	399	
	US	5	8	7	6	7	5	2	03/02/99	Herbig et al.	424	473	
	US	5	9	4	5	4	1	6	08/31/99	Shannon et al.	514	220	
FOREIGN PATENT DOCUMENTS													

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								ATTY. DOCKET NO. PC9838B		SERIAL NO. 10/310,232	
								APPLICANT William J. Curatolo, et al.		GROUP 1615	
								FILING DATE December 5, 2002			

									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
EP	0	0	8	0	3	4	1	✓	01.06.83	Europe	A61K	9/22		
EP	0	2	5	9	1	1	3	✓	09.03.88	Europe	A61K	9/22		
EP	0	3	5	7	3	6	9	✓	07.03.90	Europe	A61K	9/22		
EP	0	4	2	5	6	1	2	✓	08.05.91	Europe	F15C	5/00		
EP	0	4	1	5	6	1	3	✓	06.03.91	Europe	A61K	31/135		
EP	0	4	2	9	1	8	9	✓	29.05.91	Europe	A61K	31/135		
EP	0	7	6	8	0	8	3	✓	16.04.97	Europe	A61K	31/135		
WO	9	0	1	4	0	7	7	✓	29.11.90	International	A61K	9/52		
WO	9	2	0	0	1	0	3	✓	09.01.92	International	A61K	45/06		
WO	9	2	1	8	0	0	5	✓	29.10.92	International	A01N	43/62		
WO	9	3	1	8	7	5	5	✓	30.09.93	International	A61K	9/16		
WO	9	3	2	4	1	5	4	✓	09.12.93	International	A61L	15/62		
WO	9	4	2	7	5	8	9	✓	08.12.94	International	A61K	31/135		
WO	9	6	0	9	0	4	7	✓	28.03.96	International	A61K	31/485		
WO	9	7	0	3	6	7	0	✓	06.02.97	International	A61K	31/445		
WO	9	7	3	7	6	4	0		16.10.97	International	A61K	9/22		
WO	9	9	0	1	1	1	3		14.01.99	International	A61K	9/48		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
			1995 Physician's GenRx, 5 th Edition
			1997 Physician's GenRx, 7 th Edition
			Robinson, M. J., 16 th Edition Remington's, Chapters 90 – 91, pp. 1584-1594, "Coating of Pharmaceutical Dosage Forms".
			Pages 742-743 and page 1455.
			Drug Facts and Comparisons, 1997 Edition.
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.